Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG-C in Subjects With Chronic Discogenic Lumbar Back Pain Due to Degenerative Disc Disease
NCT06144970Phase 1Not yet recruiting
- Sponsor
- Kolon TissueGene, Inc.
- Start
- Jan 2027
- Primary completion
- Jul 2028
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
01
Overview
Phase 1, randomised, double-blind trial of Invossa in degenerative disc disease (DDD) (4 arms), sponsored by Kolon TissueGene, Inc. Primary endpoint: Treatment-emergent adverse events at 12 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
Invossa
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT06144970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144970.